bionomics r&d tax incentive for fy2013

Bionomics Limited (ASX:BNO, ADR:BMICY) today announced that it has received additional
decisions from Innovation Australia in relation to the Company’s applications for an Advance Finding
under the R&D Tax Incentive.
The findings received confirm that certain overseas expenditure totaling $17.42 million is eligible for
the R&D Tax Incentive for the three years commencing 1 July 2012.
The findings cover Bionomics’ cancer stem cell targeting antibody BNC101 and other programs within
Bionomics’ pipeline.
The new findings are in addition to those previously announced on 15 January 2013 for Bionomics’
BNC105 and BNC375 programs totaling $8.9 million over three years from 1 July 2011.
Bionomics recently reported an estimated R&D Tax Incentive refund of $7m for the year ended 30
June 2013.
“With BNC101 on target to enter clinical trials in 2014, the R&D Tax Incentive provides important
funding which enables Bionomics to remain globally competitive and at the forefront of the emerging
area of cancer treatment. Priority therapeutic targets for BNC101 are in the treatment of colon,
pancreatic and breast cancers” said Bionomics CEO & Managing Director Dr Deborah Rathjen